Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027819 (
neuroblastoma
)
27,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Neuroblastoma
tumors show a complex interaction of genetic abnormalities, among which some are of significant prognostic importance; however, analysis of chromosome changes in this tumor is often unsuccessful. Twenty primary tumors were studied by comparative genomic hybridization (CGH), and abnormalities were found in 19. While these changes included deletions of chromosome arm Ip (45%) and
MYCN
oncogene amplification (30%), gains of chromosome 17 material were much more frequent (75%). We also found evidence in two cases of a new amplification site at band 2p23.
...
PMID:Comparative genomic hybridization study of primary neuroblastoma tumors. United Kingdom Children's Cancer Study Group. 907 68
Fluorescence in situ hybridization (FISH) was applied to
neuroblastoma
for detection of N-myc (
MYCN
) oncogene amplification, and the results were compared with Southern blot analysis (Southern). In nine neuroblastomas (formalin-fixed paraffin-embedded tissues were available in seven cases including two cases with touch preparations, and two cell lines), all five cases with N-myc amplification detected by Southern had cells with multiple N-myc signals by FISH, and three cases showed no N-myc amplification either by Southern or FISH procedure. One case, not examined by Southern, showed amplified signals of N-myc by FISH. These data indicate that FISH results for N-myc amplification have close correlation with Southern blot analysis. The chromosome 2-specific repetitive DNA probe was also applied for the analysis of ploidy by FISH. Six cases with N-myc amplification by Southern and/or FISH had diploid tumors and two cases without amplified N-myc showed aneuploidy. The remaining one case consisted of heterogeneous elements showing diploidy in undifferentiated tissue and both aneuploidy (ganglionic cells) and diploidy (Schwann cells) in differentiated area. We conclude that FISH is a practical, useful and reliable method over Southern especially for analysis of N-myc amplification in
neuroblastoma
, and simultaneous cohybridization with a specific chromosome probe is of great value in predicting the prognosis of patients.
...
PMID:Application of fluorescence in situ hybridization to detect N-myc (MYCN) gene amplification on paraffin-embedded tissue sections of neuroblastomas. 918 Sep 16
The
MYCN
oncogene is amplified in 20% of childhood
neuroblastoma
and is associated independently with poor prognosis. Alteration of the p53 tumor supressor gene, in contrast, occurs infrequently in these tumors. In this report, we described a 3-year-old girl with stage IV
neuroblastoma
. Molecular analysis revealed, both
MYCN
gene amplification and a point mutation of the p53 tumor supressor gene. To our knowledge, this is the first reported case of
neuroblastoma
with genetic alterations of both these genes.
...
PMID:Concomitant p53 mutation and MYCN amplification in neuroblastoma. 921 45
The proto-oncogene
MYCN
is often amplified in human neuroblastomas. The assumption that the amplification contributes to tumorigenesis has never been tested directly. We have created transgenic mice that overexpress
MYCN
in neuroectodermal cells and develop
neuroblastoma
. Analysis of tumors by comparative genomic hybridization revealed gains and losses of at least seven chromosomal regions, all of which are syntenic with comparable abnormalities detected in human neuroblastomas. In addition, we have shown that increases in
MYCN
dosage or deficiencies in either of the tumor suppressor genes NF1 or RB1 can augment tumorigenesis by the transgene. Our results provide direct evidence that
MYCN
can contribute to the genesis of
neuroblastoma
, suggest that the genetic events involved in the genesis of
neuroblastoma
can be tumorigenic in more than one chronological sequence, and offer a model for further study of the pathogenesis and therapy of
neuroblastoma
.
...
PMID:Targeted expression of MYCN causes neuroblastoma in transgenic mice. 921 16
Deletions of chromosome arm 1p and amplification of the
MYCN
oncogene are well-recognized genetic changes in
neuroblastoma
cells. Technical difficulties in cytogenetic analysis of this tumour have hampered the recognition of other recurring abnormalities, but recent use of molecular cytogenetic techniques has indicated significant involvement of chromosome arm 17q. In primary tumours and in cell lines, a recurrent unbalanced translocation t(1p;17q) has been identified by fluorescence in situ hybridization. We confirm the occurrence of this translocation in primary tumours and, in addition, we describe seven new structural rearrangements all of which result in gain of 17q in tumour cells. These rearrangements involved chromosome arms 9p, 10q, 11p, 14q, and 16q. Triplication of the 17q arm was seen in one case. The 17q breakpoint was most commonly q21. All these 17q changes were found in near-diploid tumours. We have also reviewed the literature for
neuroblastoma
karyotypes involving 17q abnormalities; taken in conjunction with our findings this indicates a remarkable promiscuity of translocation partners, with more than 20 different chromosome regions involved in 17q translocations.
...
PMID:Promiscuous translocations of chromosome arm 17q in human neuroblastomas. 921 94
Deletions of the short arm of chromosome 1 and
MYCN
amplification are the most frequently encountered genetic changes in disseminated neuroblastomas and
neuroblastoma
cell lines. Different strategies have been followed for detection of these and other genomic changes in
neuroblastoma
including karyotyping, FISH, and LOH, each with its own limitations. Here we report upon the evaluation of comparative genomic hybridization (CGH) in the analysis of
neuroblastoma
cell lines, with the emphasis on the assessment of the reliability of CGH for the detection of distal 1p deletions. We have analyzed seven
neuroblastoma
cell lines for which the 1p status was previously studied in detail using FISH and LOH. Our results show that CGH allows reliable detection of distal 1p deletions, including a small interstitial deletion in cell line SK-N-AS. Furthermore, CGH also allows the detection of chromosomal imbalance which would otherwise remain undetected, and provides useful information for further molecular characterization of chromosomal imbalances.
...
PMID:Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines. 928 97
Neuroblastoma
has been associated genetically with amplification of the
MYCN
gene and with alteration of the short arm of chromosome 1 (1p). In pursuit of determining the spectrum of genetic loci damaged recurrently in
neuroblastoma
cells we have recently encountered two additional types of genomic abnormalities: i.) duplication of the
MYCN
gene on chromosome 2p24; and ii.) amplification of the gene MDM2. These alterations extend the spectrum of genetic lesions in
neuroblastoma
cells, although their incidence in primary tumor tissues has not been determined as yet.
...
PMID:New genetic loci in neuroblastoma. 929 45
Amplification of
MYCN
portends rapid tumor progression and poor prognosis in
neuroblastoma
.
MYCN
copy number has been described as homogeneous within a tumor and congruent in primary tumor and metastasis. We report a child with stage III favorable histology stroma-rich
neuroblastoma
(ganglioneuroblastoma) and a poor outcome with an apparent change in
MYCN
gene amplification by Southern blot. Initial biopsy revealed a ganglioneuroblastoma with predominance of differentiating cells designated as
neuroblastoma
, stroma-rich, intermixed (Shimada). Southern blot failed to demonstrate
MYCN
gene amplification. After front-line chemotherapy failed, a total resection was performed. In this specimen, Southern blot demonstrated
MYCN
amplification (15-20 copies) in the undifferentiated component and no amplification in the differentiated. Fluorescence in situ hybridization (FISH) analysis performed retrospectively on both tumor biopsies demonstrated
MYCN
amplification in the undifferentiated sections of both tumor specimens but not in the differentiated ones. This is the first well-documented case report of heterogeneous
MYCN
amplification in a child with
neuroblastoma
. Because key therapeutic decisions are based on the presence of
MYCN
amplification, physicians diagnosing and treating children with
neuroblastoma
need to be aware of the possibility that
MYCN
amplification may be heterogeneous within a tumor and may be missed using techniques based on pooled DNA such as Southern blotting. FISH may be a preferable method for determining
MYCN
amplification.
...
PMID:Heterogeneity of MYCN amplification in a child with stroma-rich neuroblastoma (ganglioneuroblastoma). 935 27
MYCN
amplification has been observed in diverse neuronal tumors including
neuroblastoma
, retinoblastoma, and small cell carcinoma of the lung, and has been correlated with a poor prognosis in advanced-stage neuroblastomas. Recent studies have shown a co-amplification of DDXI, a DEAD box gene, and
MYCN
in retinoblastoma and
neuroblastoma
. DDXI has been mapped to within a megabase of the
MYCN
gene in band 2p24. In the present study, the relational map of DDXI and
MYCN
by fluorescence in situ hybridization (FISH) mapping to metaphase cells and extended free chromatin fibers indicated that DDXI is telomeric to
MYCN
. Dual-color FISH analysis of amplicons within arrays of extended chromatin fibers was performed to examine the physical relationship of
MYCN
and DDXI within double minute chromosomes (dmins) and homogeneously staining regions (hsrs). No regular reiterated amplicon repeat unit was present in the hsrs, but detailed analysis of the configurations of DDXI and
MYCN
within each array indicated that multiple rearrangements generated a complex hsr amplicon structure. Similarly, analysis of a cell line bearing dmins showed that a composite amplicon structure involving deletions and/or duplications of
MYCN
and DDXI is a feature of dmin formation. These data are consistent with a molecular mechanism involving many rearrangements during the evolution of gene amplification, resulting in complex amplicon structures with distinct changes in relative gene copy number and considerable variation in intragenic distances between coamplified genes.
...
PMID:Relational mapping of MYCN and DDXI in band 2p24 and analysis of amplicon arrays in double minute chromosomes and homogeneously staining regions by use of free chromatin FISH. 936 31
Gain of chromosome arm 17q has recently been reported in
neuroblastoma
tumours. We analysed 17q status in relation to other known prognostic features and clinical outcome in a series of 45 tumours. Chromosome 17 status was detected by cytogenetic analysis, fluorescence in situ hybridisation (FISH) anc comparative genomic hybridisation (CGH) and correlated with other clinical and genetic factors. Survival analysis was calculated by the Kaplan-Meier estimation. Twenty-eight out of 45 tumours showed 17q gain, and this was associated with established indicators of poor prognosis; stage 4 disease (P < 0.001), age above 1 year at diagnosis (P < 0.001), 1p deletion (P < 0.01),
MYCN
amplification (P = 0.03) and diploidy/tetraploidy (P = 0.04). 17q gain was associated with poor outcome: 3-year survival was 13.5% compared with 100% for tumours without 17q gain (P = 0.0001); and progression-free survival (PFS) was 8.1% after 3 years compared with 83% for 17q normal tumours (P = 0.0001). PFS in 28
MYCN
non-amplified patients indicated that 17q status has discriminatory power within this group: PFS 0% for 17q gain (n = 14) versus 100% for normal 17q (n = 14) (P = 0.0001). This study indicates that 17q changes have prognostic significance in
neuroblastoma
and should be a target for molecular cytogenetic detection at diagnosis.
...
PMID:Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group. 938 25
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>